Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Stote

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology and Therapeutics|September 1, 1983
A new oral renal vasodilator, fenoldopamR M Stote, J W Dubb, R G Familiar, et al.
Clinical Pharmacology and Therapeutics|March 1, 1987
The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamicsN L Allison, J W Dubb, J A Ziemniak, et al.
Lancet (London, England)|April 25, 1981
Pulmonary osteoarthropathy preceding evidence of metastases from hypernephromaN L Allison, R M Stote, R Rai, et al.
Nephron|January 1, 1979
Ticrynafen: site of natriuretic activityR M Stote, J W Dubb, R Familiar, et al.
Clinical Pharmacology and Therapeutics|June 1, 1987
Effect on the endocrine system of a new dopaminergic agent, ibopamineJ T Soreth, J W Dubb, N L Allison, et al.
Clinical Pharmacology and Therapeutics|June 1, 1979
Studies with a PNMT inhibitorJ W Dubb, R M Stote, F Alexander, et al.
Hospital Practice (Office Ed.)|October 15, 1990
Metabolic acidosis in a diabetic manB E Ilson, P S Bland, N L Allison, et al.
The Journal of International Medical Research|January 1, 1986
Temelastine, a new H1-receptor antagonistF Alexander, R M Stote, N Allison, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 1, 1992
Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipientsD K Jorkasky, P Audet, N Shusterman, et al.
Journal of Cardiovascular Pharmacology|February 1, 1988
Selectivity of metoclopramide for endocrine versus renal effects of dopamine in normal humansA L Blumberg, J W Dubb, N L Allison, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|September 1, 1983
A new oral renal vasodilator, fenoldopamR M Stote, J W Dubb, R G Familiar, et al.
Clinical Pharmacology and Therapeutics|March 1, 1987
The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamicsN L Allison, J W Dubb, J A Ziemniak, et al.
Lancet (London, England)|April 25, 1981
Pulmonary osteoarthropathy preceding evidence of metastases from hypernephromaN L Allison, R M Stote, R Rai, et al.
Nephron|January 1, 1979
Ticrynafen: site of natriuretic activityR M Stote, J W Dubb, R Familiar, et al.
Clinical Pharmacology and Therapeutics|June 1, 1987
Effect on the endocrine system of a new dopaminergic agent, ibopamineJ T Soreth, J W Dubb, N L Allison, et al.
Clinical Pharmacology and Therapeutics|June 1, 1979
Studies with a PNMT inhibitorJ W Dubb, R M Stote, F Alexander, et al.
Hospital Practice (Office Ed.)|October 15, 1990
Metabolic acidosis in a diabetic manB E Ilson, P S Bland, N L Allison, et al.
The Journal of International Medical Research|January 1, 1986
Temelastine, a new H1-receptor antagonistF Alexander, R M Stote, N Allison, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 1, 1992
Fenoldopam reverses cyclosporine-induced renal vasoconstriction in kidney transplant recipientsD K Jorkasky, P Audet, N Shusterman, et al.
Journal of Cardiovascular Pharmacology|February 1, 1988
Selectivity of metoclopramide for endocrine versus renal effects of dopamine in normal humansA L Blumberg, J W Dubb, N L Allison, et al.
Pageof 3